GLP-3 (R)

Product Description

Concentration

• 10 mg per vial

Physical Form

• White lyophilized powder

Product Features

• Freeze‑dried peptide in a sterile 3 mL vial
  
  
• Butyl rubber stopper allows multiple punctures while maintaining a secure seal
  
  
• RTF vials are depyrogenated and ETO‑sterilized
  
  
• Tamper‑evident aluminum flip‑top for added protection

Research Highlights (bullet format)

• Triple Receptor Agonism: GLP‑3 is designed to activate GLP‑1, GIP, and glucagon receptors simultaneously, combining appetite suppression with higher basal metabolism for a dual‑pathway fat‑loss effect.
  
  
• Enhanced Energy Expenditure: GCGR activation mobilizes glycogen and lipids, raising resting metabolic rate and promoting continuous fat oxidation—even during sleep.
  
  
• Appetite & Gastric Modulation: Potent GLP‑1R and GIPR activity delays gastric emptying and strengthens satiety signals, reducing overall caloric intake without excessive GI discomfort.
  
  
• Albumin‑Binding Backbone: A fatty‑acid acylated design extends circulation time, enabling once‑weekly dosing in research and ensuring sustained receptor engagement.
  
  
• Early Weight‑Loss Data: Pre‑clinical and Phase 2 studies report body‑weight reductions of up to ~24 % over 48 weeks, along with smaller waist circumference, lower triglycerides, and improved HbA1c.
  
  
• Metabolic & Cardiovascular Potential: Current studies explore benefits for insulin sensitivity, lipid regulation, and cardiac function through combined incretin‑ and glucagon‑mediated pathways.

Synonyms / Registry: LY3437943 · 2381089‑83‑2

Important Terms

For research use only (RUO). Not intended for human consumption or for use in medical, veterinary, or household applications. By purchasing this product, you agree to comply with all stated Terms & Conditions.